News and Trends 8 Jan 2026 Can the thymus be drugged? TECregen raises $12 million to find out Find out about TECregen’s, a Basel-based company developing novel biologics designed to rejuvenate the thymus, “thymopoietics.” January 8, 2026 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 12 Nov 2025 Swiss biotech going strong in 2025: 19 companies to put on your radar Switzerland is a booming biotech hotspot in Europe boasting many high-profile companies. Here are 19 promising Swiss biotech companies. November 12, 2025 - 20 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 22 Oct 2025 Deal after deal: Novartis spends billions in 2025 Novartis has been on a shopping spree of late. Find out about the pharma giant’s latest deals of 2025. October 22, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 11 Apr 2025 Basel: What’s behind the success of one of Europe’s leading biotech hubs? Find out what makes Basel’s biotech hub so successful, as it has cemented its place as one of Europe’s brightest life sciences ecosystems. April 11, 2025 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
More News! 27 May 2024 New report shows that Swiss biotech capital investment surged last year With a record revenue of $8 billion in 2023, Swiss biotech appears robust in 2024. Delve into the findings of the Swiss Biotech Report 2024. May 27, 2024 - 5 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 3 Jan 2024 The top-performing countries in biotechnology (according to the OECD) Explore the OECD’s top-performing countries for biotech, from the U.S. powerhouse to the promising landscapes of the U.K., Belgium, and more. January 3, 2024 - 14 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2023 New drug helps prostate cancer patients Researchers at the Paul Scherrer Institute (PSI) in Switzerland have developed a new drug that could increase the survival chances of patients with metastatic prostate cancer. The drug is now being tested on patients in the PROGNOSTICS project. A research consortium consisting of the PSI, the University Hospital Basel and ETH Zurich is receiving CHF […] July 4, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2023 Swiss researchers develop new class of antibiotics to fight resistant bacteria Health professionals are in urgent need of new antibiotics to tackle resistant bacteria. Researchers at the University of Zurich (UZH), in Switzerland, and the company Spexis, have now modified the chemical structure of naturally occurring peptides to develop antimicrobial molecules that bind to novel targets in the bacteria’s metabolism. Each year, more than five million […] June 1, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2023 Lonza boosts ADC portfolio with Synaffix acquisition Lonza has acquired Synaffix B.V., a biotech company focused on commercializing its clinical-stage technology platform for the development of antibody drug conjugates (ADCs). While ADCs offer widespread and targeted treatment potential against cancer, they present a range of complex development and manufacturing challenges. Supported by a team of scientific experts, the Synaffix technology platform, which […] June 1, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 Molecular Partners presenting positive solid tumor data Molecular Partners AG will present additional positive data from the ongoing phase 1 study of MP0317, a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment by anchoring to fibroblast activation protein (FAP), at the 2023 ASCO (American Society of Clinical Oncology) annual meeting, June 2 to 6 in Chicago, U.S. The […] May 30, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2023 Ironwood acquires VectivBio in $1B deal Ironwood Pharmaceuticals, Inc., a GI-focused healthcare company, and VectivBio Holding AG, a clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, have entered into a definitive agreement for Ironwood to acquire VectivBio for $17.00 per share in an all-cash transaction with an estimated aggregate consideration of approximately $1 billion, net of VectivBio […] May 23, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 May 2023 Diagnosing inflammatory diseases with synthetic peptides Common inflammatory disorders such as ulcerative colitis and Crohn’s disease can be diagnosed or monitored by measuring the protein calprotectin in stool samples, while serum levels of calprotectin could be used to monitor the inflammation status in rheumatoid arthritis. Calprotectin concentrations in patient samples are typically determined using antibodies that bind and detect the protein, […] May 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email